全文获取类型
收费全文 | 25957篇 |
免费 | 1599篇 |
国内免费 | 179篇 |
专业分类
耳鼻咽喉 | 289篇 |
儿科学 | 592篇 |
妇产科学 | 524篇 |
基础医学 | 3786篇 |
口腔科学 | 300篇 |
临床医学 | 2426篇 |
内科学 | 6555篇 |
皮肤病学 | 389篇 |
神经病学 | 2180篇 |
特种医学 | 1117篇 |
外国民族医学 | 8篇 |
外科学 | 4511篇 |
综合类 | 83篇 |
一般理论 | 4篇 |
预防医学 | 1387篇 |
眼科学 | 315篇 |
药学 | 1392篇 |
中国医学 | 41篇 |
肿瘤学 | 1836篇 |
出版年
2023年 | 143篇 |
2022年 | 237篇 |
2021年 | 644篇 |
2020年 | 392篇 |
2019年 | 613篇 |
2018年 | 727篇 |
2017年 | 492篇 |
2016年 | 596篇 |
2015年 | 770篇 |
2014年 | 989篇 |
2013年 | 1268篇 |
2012年 | 1999篇 |
2011年 | 1963篇 |
2010年 | 1135篇 |
2009年 | 1138篇 |
2008年 | 1753篇 |
2007年 | 1772篇 |
2006年 | 1750篇 |
2005年 | 1774篇 |
2004年 | 1637篇 |
2003年 | 1524篇 |
2002年 | 1439篇 |
2001年 | 235篇 |
2000年 | 180篇 |
1999年 | 247篇 |
1998年 | 277篇 |
1997年 | 236篇 |
1996年 | 195篇 |
1995年 | 167篇 |
1994年 | 122篇 |
1993年 | 147篇 |
1992年 | 129篇 |
1991年 | 109篇 |
1990年 | 99篇 |
1989年 | 76篇 |
1988年 | 70篇 |
1987年 | 54篇 |
1986年 | 66篇 |
1985年 | 55篇 |
1984年 | 49篇 |
1983年 | 54篇 |
1982年 | 47篇 |
1981年 | 51篇 |
1980年 | 40篇 |
1979年 | 38篇 |
1978年 | 27篇 |
1977年 | 21篇 |
1975年 | 21篇 |
1973年 | 18篇 |
1969年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 13 毫秒
141.
142.
N Entz-Werle S Suciu J van der Werff ten Bosch E Vilmer Y Bertrand Y Benoit G Margueritte E Plouvier P Boutard E Vandecruys A Ferster P Lutz A Uyttebroeck C Hoyoux A Thyss X Rialland L Norton M-P Pages N Philippe J Otten C Behar 《Leukemia》2005,19(12):2072-2081
The first EORTC (European Organization of Research and Treatment of Cancer) acute myeloblastic leukemia (AML) pilot study (58872) was conducted between January 1988 and December 1991. Out of 108 patients, 78% achieved complete remission (CR), and event-free survival (EFS) and survival rates (s.e., %) at 7 years were 40 (5) and 51% (6%), respectively. It indicated that mitoxantrone could be substituted for conventional anthracyclines in the treatment of childhood AML without inducing cardiotoxicity. The aim of the next EORTC 58921 trial was to compare the efficacy and toxicity of idarubicin vs mitoxantrone in initial chemotherapy courses, further therapy consisting of allogeneic bone marrow transplantation (alloBMT) in patients with an HLA-compatible sibling donor or chemotherapy in patients without a donor. Out of 177 patients, recruited between October 1992 and December 2002, 81% reached CR. Overall 7-year EFS and survival rates were 49 (4) and 62% (4%), respectively. Out of 145 patients who received the first intensification, 39 had a sibling donor. In patients with or without a donor, the 7-year disease-free survival (DFS) rate was 63 (8) and 57% (5%) and the 7-year survival rate was 78 (7) and 65% (5%), respectively. Patients with favorable, intermediate and unfavorable cytogenetic features had a 5-year EFS rate of 57, 45 and 45% and a 5-year survival rate of 89, 67 and 53%, respectively. 相似文献
143.
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). 总被引:9,自引:0,他引:9
Rogerio C Lilenbaum James E Herndon Marcy A List Chris Desch Dorothy M Watson Antonius A Miller Stephen L Graziano Michael C Perry Wayne Saville Philippe Chahinian Jane C Weeks Jimmie C Holland Mark R Green 《Journal of clinical oncology》2005,23(1):190-196
PURPOSE: We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer. PATIENTS AND METHODS: A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in combination with carboplatin. RESULTS: The response rate was 17% in the paclitaxel arm and 30% in the carboplatin-paclitaxel arm (P < .0001). Median failure-free survival was 2.5 months in the paclitaxel arm and 4.6 months in the carboplatin-paclitaxel arm (P = .0002). Median survival times were 6.7 months (95% CI, 5.8 to 7.8) and 8.8 months (95% CI, 8.0 to 9.9), and 1-year survival rates were 32% (95% CI, 27% to 38%), and 37% (95% CI, 32% to 43%), respectively. The overall survival distributions were not statistically different: hazard ratio = 0.91 (95% CI, 0.77 to 1.17; P = .25). Hematological toxicity and nausea were more frequent in the combination arm, but febrile neutropenia and toxic deaths were equally low in both arms. There was no significant survival difference in elderly patients. Performance status 2 patients treated with combination chemotherapy had a better survival rate than those treated with single-agent therapy (P = .019). CONCLUSION: Combination chemotherapy improves response rate and failure-free survival compared with single-agent therapy, but there was no statistically significant difference in the primary end point of overall survival. The results in elderly patients were similar to younger patients. Performance status 2 patients had a superior outcome when treated with combination chemotherapy. 相似文献
144.
Karim Boudjema Philippe Compagnon Eric Dupont-Bierre Richard Lorho Mohamed Lakehal Anne-Sophie Thirouard Bernard Meunier Michel Messner 《Cancer radiothérapie》2005,9(6-7):458-463
Hepatocellular carcinoma (HCC) is the most frequent primitive cancer of the liver. It mostly develops on cirrhotic livers. Orthotopic liver transplantation is the only treatment that definitively addresses both the metachronous occurrence risk of HCC and the underlying disease. Under Milan criteria, i.e. less than 3 nodules of 3 cm max in diameter, or 1 nodule of 5 cm maximum, OLT has been shown effective and provides with survival rates almost equal to those obtained with HCC free cirrhotic patients. In Rennes, 195 patients with early HCC on cirrhotic livers have been transplanted from January 1995 to June 2005. Global and disease free 8 years patient survival rates were 73 and 70%, respectively. These results were significantly altered when the recipient was female, the cirrhosis due to C virus and the patient of B blood group. Despite these excellent results, the principal limit to the application of transplantation for HCC remains the long period of time patients have to wait for a graft. During this period of time, growth of the tumour may drop the patient out of Milan criteria and subsequently from the waiting list. The role of chemoembolisation, liver resection and thermal ablation while the patient is waiting for a graft remains debatable. 相似文献
145.
146.
Milena Kohn Marc Delord Maureen Chbat Amina Guemriche Fatiha Merabet Anne-Laure Roupie Naelle Lombion Hassan Farhat Thomas Longval Aurlie Cabannes-Hamy Juliette Lambert Stphanie Marque-Juillet Victoria Raggueneau Jennifer Osman Marc Spentchian Sophie Rigaudeau Philippe Rousselot Caroline Besson 《Haematologica》2022,107(6):1454
147.
Marcelo Capra Thomas Martin Philippe Moreau Ross Baker Ludek Pour Chang-Ki Min Xavier Leleu Mohamad Mohty Marta Reinoso Segura Mehmet Turgut Richard LeBlanc Marie-Laure Risse Laure Malinge Sandrine Schwab Meletios Dimopoulos 《Haematologica》2022,107(6):1397
Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: ) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate <60 mL/min/1.73 m². Addition of Isa prolonged progression-free survival (PFS) in patients with RI (hazard ratio: 0.27; 95% confidence interval [CI]: 0.11–0.66; median PFS not reached for Isa-Kd versus 13.4 months for Kd [20.8-month follow-up]). Complete renal responses occurred more frequently with Isa-Kd (52.0%) versus Kd (30.8%) and were durable in 32.0% versus 7.7% of patients, respectively. Treatment exposure was longer with Isa-Kd, with median number of started cycles and median duration of exposure of 20 versus 9 cycles and 81.0 versus 35.7 weeks for Isa-Kd versus Kd, respectively. Among patients with RI, the incidence of patients with grade ≥3 treatment-emergent adverse events was similar between the two arms (79.1% in Isa-Kd vs. 77.8% in Kd). In summary, the addition of Isa to Kd improved clinical outcomes with a manageable safety profile in patients with RI, consistent with the benefit observed in the overall IKEMA study population. NCT03275285相似文献
148.
Zied Chaari Franois Montagne Matthieu Sarsam Benjamin Bottet Philippe Rinieri Andre Gillibert Jean Marc Baste 《Interactive Cardiovascular and Thoracic Surgery》2022,34(6):1016
Open in a separate window OBJECTIVESOur goal was to report our midterm results using imaging-assisted modalities with robotic segmentectomies for non-small-cell lung cancer (NSCLC).METHODSThis was a retrospective study of all robotic segmentectomies, with confirmed NSCLC, performed at our general and thoracic surgery unit in the Rouen University Hospital (France), from January 2012 through December 2019. Benign and metastatic lesions were excluded. Data were extracted from the EPITHOR French nationwide database.RESULTSA total of 121 robotic segmentectomies were performed for 118 patients with a median age of 65 (interquartile range: 60, 69) years. The majority had clinical stage T1aN0M0 (71.9%) or T1bN0M0 (13.2%). The mean (standard deviation) number of resected segments was 1.93 (1.09) with 80.2% imaging-assisted segmentectomies. Oriented (according to tumour location) or systematic lymphadenectomy or sampling was performed for 72.7%, 23.1% and 4.1% of patients. The postoperative course was uneventful for 94 patients (77.7%), whereas 34 complications occurred for 27 patients (22.3%), including 2 patients (1.7%) with Clavien-Dindo ≥III complications. The mean thoracic drainage duration was 4.12 days, and the median hospital stay was 4 days (interquartile range: 3, 5) after the operation. The 2-year survival rate was 93.9% (95% confidence interval: 86.4–97.8%). Excluding stage IV (n = 3) and stage 0 tumours (n = 6), the 2-year survival rate was 95.7% (95% confidence interval: 88.4–98.8%) compared to an expected survival rate of 94.0% according to stage-specific survival rates found in a large external reference cohort.CONCLUSIONSImaging-guided robotic-assisted thoracic surgery segmentectomy seems to be useful and oncological with good midterm results, especially for patients with early-stage NSCLC. 相似文献
149.
Marie-Hlne Denault Catherine Labb Carolle St-Pierre Brigitte Fournier Andranne Gagn Claudia Morillon Philippe Joubert Serge Simard Simon Martel 《Current oncology (Toronto, Ont.)》2022,29(5):3187
Lung cancer is the leading cause of cancer death worldwide, with a five-year survival of 22% in Canada. Guidelines recommend rapid evaluation of patients with suspected lung cancer, but the impact on survival remains unclear. We reviewed medical records of all patients with newly diagnosed lung cancer in four hospital networks across the province of Quebec, Canada, between 1 February and 30 April 2017. Patients were followed for 3 years. Wait times for diagnosis and treatment were collected, and survival analysis using a Cox regression model was conducted. We included 1309 patients, of whom 39% had stage IV non-small cell lung cancer (NSCLC). Median wait times were, in general, significantly shorter in patients with stage III–IV NSCLC or SCLC. Surgery was associated with delays compared to other types of treatments. Median survival was 12.9 (11.1–15.7) months. The multivariate survival model included age, female sex, performance status, histology and stage, treatment, and the time interval between diagnosis and treatment. Longer wait times had a slightly protective to neutral effect on survival, but this was not significant in the stage I–II NSCLC subgroup. Wait times for the diagnosis and treatment of lung cancer were generally within targets. The shorter wait times observed for advanced NSCLC and SCLC might indicate a tendency for clinicians to act quicker on sicker patients. This study did not demonstrate the detrimental effect of longer wait times on survival. 相似文献
150.
Humam M Kehrli T Jeannerat D Muñoz O Hostettmann K Christen P 《Journal of natural products》2011,74(1):50-53
Three tropane alkaloids, named schizanthines N, O, and P (1-3), have been isolated from the crude alkaloid extract of the endemic Chilean plant Schizanthus tricolor. On the basis of extensive NMR studies and MS fragmentation analysis, their structures were determined to be 3α-(E)-4-hydroxysenecioyloxy-6β-angeloyloxytropane (1), 3α-(E)-4-hydroxysenecioyloxy-6β-senecioyloxytropane (2), and 3α-mesaconyloxy-6β-senecioyloxytropane (3). Compounds 1 and 2 are the first isomeric alkaloids in the tropane series possessing a hydroxysenecioyl substituent as an esterifying moiety. 相似文献